Next stage of cooperation between LUMIER PHARMA LLC and F.Hoffmann-La Roche Ltd
At the beginning of 2012, LUMIER PHARMA LLC registered two medications developed by the F.Hoffmann-La Roche Ltd Company that will be produced in Ukraine in the framework of a mutual project with LUMIER PHARMA LLC:
7 February 2012
- RITUXIM (rituximab), a concentrate for the preparation of infusion solution in vials of 100mg/10 ml and 500mg/50 ml – for the treatment of non-Hodgkin's lymph, chronic lymphatic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis.
- TRASTUMAB (trastuzumab), powder for the preparation of concentrate for infusion, in vials of 150 mg each – for the treatment of HER-2 positive metastatic or early breast cancer.